Liu Dongying, Wen Qing, Liu Min, Gao Yang, Luo Lihong, Zhang Zhuo, Chen Qiu
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Medicine (Baltimore). 2020 May;99(20):e20347. doi: 10.1097/MD.0000000000020347.
The number of prediabetic individuals is at a high level worldwide and they have an increased risk of developing diabetes, causing severe physical impairment and heavy financial burden. Recently, using various dietary supplements is increasingly common, and relevant trials of different diseases are increasing correspondingly. The effects of dietary supplements have been confirmed in some studies among prediabetic individuals. However, there remains no comprehensive systematic review to assess the efficacy and safety of dietary supplements intake in prediabetic individuals.
We plan to search and retrieve applicable randomized controlled trials of dietary supplements for prediabetic individuals in the following databases before June 2020: PubMed, Web of Science, EMBASE, the Cochrane Library, the Cochrane Central Register of Controlled Trials(CENTRAL), Allied and Complementary Medicine Database(AMED), Chinese Biomedical Literature database, Wan Fang database, Chinese Scientific Journal database (VIP), Chinese National Knowledge Infrastructure database(CNKI), and the ClinicalTrials.gov website. Two reviewers will separately perform study selection, data extraction, methodological quality assessment and quality of evidence assessment. Data analysis and publication bias will be conducted by Review Manager 5.3.
This evidence-based medicine systematic review will prove the efficacy and safety of multifarious dietary supplements for prediabetes.
As this systematic review is based merely on already published literature, no approval of the ethics committee is required. We will disseminate this systematic review to a peer-reviewed journal.
INPLASY202040057.
全球糖尿病前期个体数量众多，他们患糖尿病的风险增加，会导致严重的身体损伤和沉重的经济负担。近年来，使用各种膳食补充剂越来越普遍，针对不同疾病的相关试验也相应增加。一些研究已证实膳食补充剂对糖尿病前期个体的作用。然而，目前尚无全面的系统评价来评估糖尿病前期个体摄入膳食补充剂的疗效和安全性。
我们计划在2020年6月前检索以下数据库中适用于糖尿病前期个体膳食补充剂的随机对照试验：PubMed、科学网、EMBASE、考克兰图书馆、考克兰对照试验中心注册库（CENTRAL）、补充与替代医学数据库（AMED）、中国生物医学文献数据库、万方数据库、中文科技期刊数据库（维普）、中国知网数据库（CNKI）以及ClinicalTrials.gov网站。两名评审员将分别进行研究筛选、数据提取、方法学质量评估和证据质量评估。数据分析和发表偏倚将采用Review Manager 5.3进行。
本循证医学系统评价将证实多种膳食补充剂对糖尿病前期的疗效和安全性。
由于本系统评价仅基于已发表的文献，无需伦理委员会批准。我们将把本系统评价发表在同行评审期刊上。
INPLASY202040057。
